Nucala (mepolizumab) is a prescription drug used ... (This is also called a drug’s mechanism of action.) Nucala is prescribed to treat four conditions. All these conditions are caused by a ...

GSK plc GSK announced that the FDA has accepted its regulatory filing, seeking the approval of a new indication for Nucala (mepolizumab ... with a novel mechanism of action that targets IL ...

FASENRA demonstrated noninferiority to mepolizumab for both the primary ... 8 Results are descriptive only. FASENRA’s mechanism of action leads to near-complete depletion of eosinophils.

Depemokimab’s mechanism of action is similar to mepolizumab. Three adverse events led to discontinuation or withdrawal. 72% of patients were exacerbation-free, and 96% did not need a hospital or ...